Jorna Therapeutics is building the future of genome and transcriptome editing
<aside> 💡 At Jorna Therapeutics, we are developing the next generation tools for editing genomes and transcriptomes using cutting-edge synthetic biology, machine learning, and novel unified representations. We apply these tools to create therapeutics for genetic and degenerative diseases that are previously untreatable. We are also developing tools that can unlock previously unattainable potentials. So far, we have created novel tools that are unimaginable using traditional methods such as genome/metagenome mining, and they have produced profound impacts already (you can read an example story here on how we created a batch of novel Cas proteins using AI). With these steps as validation, we are now inviting you to join us to create an exciting future that is powered by the tools that you will design.
</aside>
Jorna Therapeutics is a vibrant startup founded by scientists from the Broad Institute and Harvard working on AI-guided editor design and associated therapeutics. In the past, our work has helped our clients such as Sherlock Biosciences and the Gates Foundation tackle some unique challenges that they faced, which in turn formed the basis of our cutting-edge platform. Now we are taking on some of the most challenging problems in this field that could have a profound impact in how we treat genetic and degenerative diseases. We are inviting the most brilliant minds to join us on this exciting journey.
https://goo.gl/maps/cTRmXE6oRWE72zC3A
Jorna Therapeutics is a Quantum Sky company, and a sister company of Rosetta Bio, a proud resident of LabCentral and a recipient of Ono Pharma’s Innovation Prize. We are currently located at 700 Main St, Cambridge, MA 02139, and are scheduled to move into the new building of the Engine, built by MIT, by September, 2022.
Chengwei Luo, PhD
Founder and Exec. Chairman
Vincent DiGiacomo, PhD
Director, Therapeutic Innovations
Mao Taketani, PhD
Director, Synthetic Biology
Enxing Zhou, PhD
Senior Scientist
Last updated: October 10th, 2022